Isatuximab intravenous (IV)
Phase 2
SanofiIsatuximab intravenous (IV) is one of 17 therapeutic programs targeting Plasma Cell Myeloma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
17 competitors in Plasma Cell Myeloma
#DrugCompanyPhaseTrials
1DARZALEX FASPRO
Johnson & JohnsonPhase 3
Medrol
PfizerPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Singulair
OOrganon and Co
Phase 3
Benadryl
PParkedale
Phase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Paracetamol
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Isatuximab intravenous (IV). EMBL-EBI & Wellcome Sanger Institute.
- [3]